Publications

CAR-T

Publications

Follicle-stimulating Hormone Receptor is Expressed by Most Ovarian Cancer Subtypes and is a Safe and Effective Immunotherapeutic Target

Breast Cancer Vaccine

Publications

Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer

Ovarian Cancer Vaccine

Publications

Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Mullerian Hormone Receptor II

Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas

Latest News & Events

May 22, 2023

Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial

Read More...

Apr 17, 2023

Anixa Biosciences Clarifies Poster Presentation on Company Website

Read More...

Apr 17, 2023

Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine

Read More...